CoChat
Sign Up
Cited by 541Acute Ischemic Stroke ManagementBlood Pressure and Hypertension StudiesIntracerebral and Subarachnoid Hemorrhage Research

The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial

Sandset, Else Charlotte, Bath, Philip MW, Boysen, Gudrun, Jatuzis, Dalius, Kõrv, Janika, Lüders, Stephan, Murray, Gordon D, Richter, Przemyslaw S +4 more·2011·The Lancet
DOI 10.1016/s0140-6736(11)60104-9
Open this paper in CoChat — free account

Abstract

Background Raised blood pressure is common in acute stroke, and is associated with an increased risk of poor outcomes. We aimed to examine whether careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure. Methods Participants in this randomised, placebo-controlled, double-blind trial were recruited from 146 centres in nine north European countries. Patients older than 18 years with acute stroke (ischaemic or haemorrhagic) and systolic blood pressure of 140 mm Hg or higher were included within 30 h of symptom onset. Patients were randomly allocated to candesartan or placebo (1:1) for 7 days, with doses increasing from 4 mg on day 1 to 16 mg on days 3 to 7. Randomisation was stratified by centre, with blocks of six packs of candesartan or placebo. Patients and investigators were masked to treatment allocation. There were two co-primary effect variables: the composite endpoint of vascular death, myocardial infarction, or stroke during the first 6 months; and functional outcome at 6 months, as measured by the modified Rankin Scale. Analyses were by intention to treat. The study is registered, number NCT00120003 (ClinicalTrials.gov), and ISRCTN13643354. Findings 2029 patients were randomly allocated to treatment groups (1017 candesartan, 1012 placebo), and data for status at 6 months were available for 2004 patients (99%; 1000 candesartan, 1004 placebo). During the 7-day treatm…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)60104-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The SCAST trial reported an OR of 1.17 (95% CI, 1.00-1.38, negative trend) for candesartan, analyzed using ordinal logistic regression.

    “Similarly, the Scandinavian Candesartan Acute Stroke Trial (SCAST) trial reported an OR of 1.17 (95% CI, 1.00-1.38, negative trend) for candesartan (analyzed using ordinal logistic regression). 28”

    From Statistical Analysis of the Primary Outcome in Acute Stroke Trials (2012) · cites this paper as [28]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sandset, E. C., Bath, P. M., Boysen, G., Jatuzis, D., Kõrv, J., Lüders, S., Murray, G. D., Richter, P. S., Roine, R. O., Terént, A., Thijs, V., & Berge, E.
Affiliations
  • Oslo University Hospital (NO)
  • University of Nottingham (GB)
  • University of Copenhagen (DK)
  • Tartu University Hospital (EE)
  • St. Josefs-Hospital Cloppenburg (DE)
  • University of Edinburgh (GB)
  • Institute of Psychiatry and Neurology (PL)
  • Turku University Hospital (FI)
  • Uppsala University (SE)
  • Universitair Ziekenhuis Leuven (BE)
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2011-02
Volume
377
Issue
9767
Pages
741-750
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(11)60104-9
OpenAlex
W2123312526
Cited by
541
References
1
Citations by year
2026: 7 · 2025: 17 · 2024: 15 · 2023: 15 · 2022: 23 · 2021: 32 · 2020: 25 · 2019: 32 · 2018: 40 · 2017: 53 · 2016: 33 · 2015: 43 · 2014: 59 · 2013: 45 · 2012: 54
FWCI
48.97
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Neurology › Intracerebral and Subarachnoid Hemorrhage Research
Keywords
candesartan, angiotensin receptor blockers, acute stroke, hypertension, blood pressure reduction, ischemic stroke, hemorrhagic stroke, functional outcome, modified Rankin Scale, vascular death, myocardial infarction, stroke recurrence, secondary prevention, antihypertensive therapy, secondary stroke prevention
MeSH terms
Aged, Aged, 80 and over, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Blood Pressure, Cerebral Hemorrhage, Brain Ischemia, Double-Blind Method, Drug Administration Schedule, Europe, Female, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Tetrazoles, Meta-Analysis as Topic, Odds Ratio, Treatment Failure, Stroke, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review